Meta AnalysisID 5910
参苓白术散治疗慢性胃炎：系统评价与Meta分析
CRD42020212979
The efficacy and safety of Shen-ling-bai-zhu-san for Chronic gastritis.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5910
- Evidence Id
- 14468
- Core Evidence Id
- 14468
- Source Meta Analysis Id
- 5893
- Herb2 Meta Analysis Id
- HBMA005893
- Crd Id
- CRD42020212979
- Title
- Shen-ling-bai-zhu-san for Chronic gastritis: a systematic review and meta-analysis
- Review Question
- The efficacy and safety of Shen-ling-bai-zhu-san for Chronic gastritis.
- Study Type Included
- All the RCTs to explore the specific efficacy and safety of SLBZS in the treatment of the disease will be included. Cross-trials, quasi-RCT, case reports, observation study, animal study, repeatedly published studies, and studies did not have access to complete data will be excluded. If we are unable to find at least five eligible RCTs for the systematic review, we will broaden our inclusion criteria to include semi-randomized control studies, non-randomized studies of SLBZS in allergic rhinitis patients using the Cochrane Effective Practice and Organization of CGZDe (EPOC) approach to categorize the types of studies.
- Condition Being Studied
- Chronic gastritis is one of the most common life-long, serious and insidious illnesses in human beings. One may estimate that more than half of the world population have this disease in some degree and extent, indicating that even many hundreds of millions of people worldwide may have chronic gastritis in a form or other. The significance of chronic gastritis as a serious disease is largely underrated in clinical practice, even though the role of gastritis in the pathogenesis of ordinary peptic ulcers and gastric cancers is obvious. One may estimate that millions of premature deaths may occur annually worldwide due to cancer and ulcer as sequelae of the chronic gastritis. Chronic gastritis appears either as nonatrophic or atrophic form. They are forms and phenotypes of gastritis which represent different stages of a same life-long disease. The morphological appearances of gastritis published are very similar worldwide, i.e., chronic gastritis is seemingly, with its sequelae, one and same disorder throughout the world.
- Participant
- Any age of Chronic gastritis participants who meet the diagnostic criteria of allergic rhinitis were all included. However, Chronic gastritis merged with other diseases were excluded. This was done because targeted drug combination methods in these studies could not be used to compare the effects. All included participants in this review regardless of their age, race, and gender.
- Animal
- Human Disease Modelled
- Intervention
- Shen-Ling-Bai-Zhu-San (SLBZS) is one of the most common formulations of TCM for the treatment of UC. A number of studies published in Chinese medical literature have reported the efficacy and safety of SLBZS in treating UC. SLBZS is a famous classic formulation in Taiping Huimin Heji Ju Fang written by the Song Dynasty officials in 1078 AD. It is mainly composed of the following 10 kinds of TCMs, including Panax Ginseng, Poria Cocos, Atractylodes Ovata, Dioscorea Batatasm, Coix Lachryma-jobi, Nelumbo Nucifera, Dolichos Lablab, Glycyrrhiza uralensis Fisch, Amomum Xanthioides, and Platycodon Grandiflorum. On the basis of the theory of TCM, SLBZS has the function of supplementing spleen and is mainly used for weakness of the spleen and stomach.
- Comparator Control
- We compared SLBZS with conventional medicine or placebo regimens. SLBZS compared with other types of Chinese herbal medicine formulas such as BuZhongYiQi decoction, and Dachengqi decoction was excluded. Interventions considered for experimental groups versus control groups were as follows: (1) SLBZS versus conventional medicine. (2) SLBZS combined with conventional medicine versus conventional medicine. (3) SLBZS combined with other complementary therapies versus other complementary therapies. (4) SLBZS versus placebo.
- Main Outcome
- Types of outcome measures Primary outcomes The primary outcomes of this review will focus on the induction of remission and the maintenance of remission. The definitions employed in the primary studies will be accepted for these outcomes. Secondary outcomes Secondary outcomes are as follows: (1)improvement of clinical symptoms; (2)changes in participant status as evaluated by quality of life; (3)adverse events; (4)cost (if available). Measures of effect Review Manager (RevMan) software version 5.3 was applied to pool our data and to execute the meta-analysis. GRADE software was the sole quality evaluation tool used to demonstrate the GRADE evidence ratings. Risk ratio (RR) was chosen for dichotomous data (efficacy, recurrence rate, and adverse events). Mean difference (MD) was chosen for variable data. Confidence interval (CI) was set at 95%, and P < 0.05 was defined as statistically significant. I² values were used to assess inter-study heterogeneity. According to the Cochrane Handbook, when I² > 75%, considerable heterogeneity was confirmed, whereupon a random effects model was applied. We pooled trials when the intervention form of those studies was adequately similar. Specific subgroups were analyzed according to similar intervention forms or similar design. Based on the practice recommendation of the Cochrane Handbook, we found that zero events in both the intervention and the control groups could be excluded from the meta-analysis.
- Outcome Measure
- Additional Outcome
- Any other items about the safety and efficacy of SLBZS for Chronic gastritis will be included. Measures of effect Review Manager (RevMan) software version 5.3 was applied to pool our data and to execute the meta-analysis. GRADE software was the sole quality evaluation tool used to demonstrate the GRADE evidence ratings. Risk ratio (RR) was chosen for dichotomous data (efficacy, recurrence rate, and adverse events). Mean difference (MD) was chosen for variable data. Confidence interval (CI) was set at 95%, and P < 0.05 was defined as statistically significant. I² values were used to assess inter-study heterogeneity. According to the Cochrane Handbook, when I² > 75%, considerable heterogeneity was confirmed, whereupon a random effects model was applied. We pooled trials when the intervention form of those studies was adequately similar. Specific subgroups were analyzed according to similar intervention forms or similar design. Based on the practice recommendation of the Cochrane Handbook, we found that zero events in both the intervention and the control groups could be excluded from the meta-analysis.
- Study Method
- Intervention, Meta-analysis, Methodology, Systematic review
- Keyword
- Drugs, Chinese Herbal; Gastritis; Humans; Phytotherapy
- Contact
- jin wei [email protected]
- Organisational Affiliation
- School of clinical medicine, Chengdu University of Traditional Chinese Medicine
- Funding Source
- Based on truncation theory and gastric purgation method, the molecular mechanism of improving intestinal homeostasis in the treatment of SAP was studied(No.20YYJC2083)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-10-06
- Registration Date
- 2020-11-05
- Anticipated Start Date
- 2020-12-30
- Anticipated Completion Date
- 2021-03-30
- Title Cn
- 参苓白术散治疗慢性胃炎：系统评价与Meta分析
- Title En
- Shen-ling-bai-zhu-san for Chronic gastritis: a systematic review and meta-analysis
- Bilingual Status
- complete